Petrella Stephanie, Cambau Emmanuelle, Chauffour Aurelie, Andries Koen, Jarlier Vincent, Sougakoff Wladimir
Laboratoire de Recherche Moléculaire sur les Antibiotiques, LRMA INSERM U655, Université Pierre et Marie Curie, F-75634 Paris Cedex 13, France.
Antimicrob Agents Chemother. 2006 Aug;50(8):2853-6. doi: 10.1128/AAC.00244-06.
The atpE gene encoding the subunit c of the ATP synthase of Mycobacterium tuberculosis, the target of the new diarylquinoline drug R207910, has been sequenced from in vitro mutants resistant to the drug. The previously reported mutation A63P and a new mutation, I66M, were found. The genetic diversity of atpE in 13 mycobacterial species was also investigated, revealing that the region involved in resistance to R207910 is conserved, except in Mycobacterium xenopi in which the highly conserved residue Ala63 is replaced by Met, a modification that may be associated with the natural resistance of M. xenopi to R207910.
编码结核分枝杆菌ATP合酶亚基c的atpE基因,是新型二芳基喹啉药物R207910的作用靶点,已对耐该药物的体外突变体进行了测序。发现了先前报道的A63P突变和一个新的I66M突变。还研究了13种分枝杆菌中atpE的遗传多样性,结果表明,除了蟾分枝杆菌外,参与对R207910耐药的区域是保守的,在蟾分枝杆菌中,高度保守的残基Ala63被Met取代,这种修饰可能与蟾分枝杆菌对R207910的天然耐药性有关。